IGF-LR3 Spray supplies IGF-LR3, also written Long R3 IGF-I or Long-[Arg3]-IGF-I, an 83-amino-acid analog of IGF-1 carrying a 13-residue N-terminal extension and an arginine substituted for glutamate at position 3. Three intramolecular disulfide bonds give it a calculated mass near 9.1 kDa, well above the short peptides elsewhere in this catalog, and it is registered under CAS 143045-27-6. Its larger size and folded structure call for identity checks beyond simple HPLC purity. Offered as a 1 mg spray-dispensed size for laboratory research use only.
Ask for the analytical documentation of any lot.
HPLC is the method used to measure purity
Ask for the report for a specific lot through the contact page
Supplied for laboratory research use only
Mass spectrometry is the method used to confirm identity
IGF-LR3 Spray is Veracue’s spray-dispensed packaging of IGF-LR3, also written Long R3 IGF-I or Long-[Arg3]-IGF-I, an 83-amino-acid analog of IGF-1 built with a 13-residue N-terminal extension, an arginine in place of glutamate at position 3, and three disulfide bonds. The underlying molecule is identical to the one documented on Veracue’s IGF-LR3 vial listing; only the packaging and dispensing format differ between the two listings.
At 83 residues and about 9.1 kDa, IGF-LR3 is considerably larger than the short peptides found elsewhere in Veracue’s catalog, and it behaves more like a small folded protein than a linear peptide chain. That size and the three disulfide bonds shape how the molecule is characterized and how its certificate of analysis should be read, regardless of packaging format.
"Spray" is a packaging and dispensing descriptor, nothing more. It does not establish a route, a concentration, or a formulation, and none of those specifics should be inferred from the product name. Chemical form, concentration, fill volume and storage conditions are reported on each lot’s own documentation and can be requested through the contact page.
| Product name | IGF-LR3 Spray (molecule also written Long R3 IGF-I, Long-[Arg3]-IGF-I) |
| Packaging format | Spray-dispensed, Research Use Only |
| Length | 83 amino acids |
| Structural changes | 13-residue N-terminal extension; Glu-to-Arg at position 3 of the IGF-1 domain |
| Calculated mass | About 9.1 kDa (9,117.6 Da reduced chain; 9,111.5 Da with three disulfide bonds) |
| CAS Registry Number | 143045-27-6 |
| UNII | M9L22Y19H9 |
| Size offered | 1 mg |
| Research designation | Research Use Only |
Masses are calculated reference values for the molecule in general, not measured results for a Veracue lot. Physical form, salt or counterion, formulation, purity, lot results and storage conditions are reported on each lot’s documentation and can be requested through the contact page.
Veracue lists IGF-LR3 in more than one packaging format because research groups source and track material differently depending on how it is packaged. Keeping the formats as separate listings keeps lot records, images and documentation specific to the packaging a researcher actually ordered, rather than mixing records across formats.
IGF-LR3 Spray and Veracue’s IGF-LR3 vial listing describe one molecule: an 83-residue analog with a 13-residue N-terminal extension, a Glu-to-Arg substitution at position 3 of the IGF-1 domain, and six cysteines forming three intramolecular disulfide bonds. Packaging format has no bearing on sequence, formula or mass, so these values are identical across both listings.
No. The compound reported under this listing is the same Long-[Arg3]-IGF-I analog reported under the vial listing. What differs between the two listings is how the material is packaged and dispensed, not its chemical identity.
In Veracue’s catalog, "Spray" is a packaging and dispensing term, comparable to "vial" or "powder" on other listings. It tells a researcher how the product is dispensed from its container. It does not specify a concentration, a carrier, a route, or a formulation, and it is not shorthand for any particular method of use. Those details, where applicable, live in lot-specific documentation rather than in the catalog name.
Treating a packaging word as a technical specification is a common source of error when comparing listings across suppliers, and the risk is no different for a large analog like IGF-LR3 than for a short peptide. A researcher documenting materials in a methods section should cite the lot’s own documentation for format-specific details rather than inferring them from the word "Spray" alone.
| Molecule | Residues | Structural change | IGFBP interaction |
|---|---|---|---|
| Native IGF-1 | 70 | Reference sequence | Normal |
| IGF-LR3 | 83 | 13-residue N-terminal extension plus Glu3-to-Arg | Markedly reduced |
| R3-IGF-I | 70 | Glu3-to-Arg without the extension | Reduced |
| Des(1-3)-IGF-I | 67 | First three residues absent | Reduced |
This table compares molecular structure and binding-protein interaction only. Catalog format is listed separately because it is a packaging detail, not a property of the molecule itself, and it does not change which receptor a given analog engages or how it interacts with IGF-binding proteins.
At 83 residues and three disulfide bonds, IGF-LR3 folds into a defined tertiary structure rather than existing as a flexible chain, which is why its research literature discusses folding and binding-protein interaction alongside receptor activation. IGF-LR3, in either packaging format Veracue offers, is studied as a tool for separating receptor engagement from IGF-binding-protein interaction, since the analog activates the type I IGF receptor while interacting with IGFBPs far less than native IGF-1 does.
Because "Spray" and "vial" describe packaging rather than chemistry, a methods section should still name the molecule precisely by sequence, CAS number or UNII, and separately note the catalog format and lot number actually used. This page provides molecular reference information and general research context only, and Veracue provides no dosing, administration or usage guidance of any kind.
Identity and purity for IGF-LR3 Spray are established the same way as for any IGF-LR3 lot: intact-mass analysis to confirm the observed mass against the expected reduced-chain or disulfide-bonded form, and reverse-phase HPLC for chromatographic purity. Because IGF-LR3 is a disulfide-rich analog rather than a short linear peptide, intact mass alone cannot separate correctly folded material from a mispaired disulfide isomer, since the two share the same mass.
Packaging format has no bearing on which analytical methods apply. A spray-dispensed lot and a vial lot of the same molecule are verified against the same sequence, formula and mass references, listed on the IGF-LR3 at a Glance table above.
| Method | Tells a researcher | Does not prove by itself |
|---|---|---|
| Intact-mass MS | Mass consistent with the reduced chain or three-disulfide form | Correct disulfide pairing; purity |
| RP-HPLC | Chromatographic purity (area %) under stated conditions | Identity or folding |
| Structural or folding evidence, where available | Whether the main species behaves like correctly folded protein | Lot activity in any particular assay |
| Formulation | What else is in the vial and how much protein it holds | Chromatographic purity |
A certificate of analysis describes one lot, never a packaging format or a compound in general. Before relying on any figure, confirm that the lot number on the certificate matches the container and the order record for the spray-format unit received.
A complete certificate separates product identity, lot number, chemical form, the mass form the observed result was matched against, RP-HPLC result, folding or structural evidence where available, test date and testing laboratory. Where concentration or fill-volume figures are relevant to a spray-format unit, they are reported on that lot’s own documentation rather than inferred from the catalog listing. The certificate page explains how to request lot documentation for either format.
No. The verification question is the same: does this lot match the stated 83-residue sequence, and is the mass result paired with its named form and a purity figure from the same lot. Packaging format does not change what counts as adequate documentation.
IGF-LR3’s reduced chain and its three-disulfide-bonded form differ by about six daltons, roughly 9,117.6 Da against 9,111.5 Da. If a lot’s documentation leaves the form unstated, a mass comparison can appear to pass or fail based on which reference value was assumed. Confirm the form on the lot’s certificate and use the matching reference mass, regardless of packaging format.
For each lot, keep the catalog listing snapshot, the lot-specific certificate, the stated mass form, the receipt date, labeled storage conditions, and the packaging format actually received. Recording format alongside the usual identity fields keeps multi-format catalogs like this one traceable lot to lot.
IGF-LR3 Spray is supplied for laboratory research and analytical characterization only. It is not intended for human or veterinary use, or for ingestion, injection or any form of administration. This page contains no dosing, administration or usage guidance of any kind, and the word "Spray" in the product name describes Veracue’s packaging and dispensing format only. See the Medical Disclaimer and the Terms and Conditions for sitewide policies.
RESEARCH PEPTIDE
Spray bottle pairing a 29-residue GHRH analog with the pentapeptide Ipamorelin, 5 mg of each and 45 sprays per bottle. Laboratory research use only.
RESEARCH PEPTIDE
GLP-T Spray pairs a 39-residue peptide, LY3298176 (CAS 2023788-19-2), with a C20 diacid on lysine 20. 10 to 60 mg, research use only, 45 sprays a bottle.
RESEARCH PEPTIDE
A 28-residue, N-acetylated peptide at 3108.3 g/mol, spray-dispensed in a 10 mg bottle with 45 sprays. Supplied for research use only.
RESEARCH PEPTIDE
Seven residues, a lactam ring and an amide terminus: Melanotan II, CAS 121062-08-6, in a 10 mg bottle of 45 sprays. Laboratory research only.
